Workflow
斐萃保健品
icon
Search documents
第一创业晨会纪要-20250611
证券研究报告 点评报告 2025 年 6 月 11 日 晨会纪要 核[心Ta观bl点e_:Summary] 第一创业证券研究所 一、产业综合组: 分析师:郭强 6 月 10 日国家发展改革委主任郑栅洁主持召开科技型民营企业座谈会,围绕科学编 制"十五五"规划,聚焦科技创新领域听取意见建议。该次座谈会的召开说明"十 五五"规划的编制工作已经开始启动。历次五年规划中的很多新领域、新方向和投 资重点都会成为资本市场关注的热点,因此后续编制会议中提到的新领域、新方向 和投资重点都将值得重点关注。 马斯克周二在 X 平台上回应使用 Model Y 做"Robotaxi"的视频时表示,这些都是 直接从工厂出来的未经改装的特斯拉汽车,这些车辆使用了一个新版本的软件,我 们有一个更先进的模型,有大约 4 倍的参数,但仍需要大量的打磨。可能几个月后 就可以部署了。在 2 到 3 年内,自动驾驶汽车将在世界各地变得非常普遍。特斯拉 的 Al/Autopilot 可能已经可以在赛道上击败最好的人类了"。马斯克表示 Robotaxi 公开试运营预计将于 6 月 22 日开始。从视频看,无人驾驶技术正在快速进步,产业 进步和发展的方向 ...
若羽臣(003010):绽家快速放量 保健品斐萃打造第二成长曲线
Xin Lang Cai Jing· 2025-04-29 02:48
品牌管理业务全链路赋能能力凸显,代运营聚焦精细化服务。1)品牌管理:24 年营收5.01 亿元,同比 +212.24%,占比提升至28.38%。公司深化与拜耳、强生等合作,赋能全链路增长,新引入DHC、Herbs of Gold等新品牌,聚焦保健品与个护领域。2)代运营:24 年营收7.64 亿元,同比-18.95%,毛利率约 +5pct,合作客户健康度持续提升。 盈利预测与投资评级:若羽臣作为国内头部数字化品牌管理公司,及时挖潜把握机遇布局家清、保健品 行业,绽家、斐萃从0 到1 破茧成蝶验证品牌孵化力,新兴业务双轮驱动,长期发展前景明朗。原有代 运营及品牌管理业务持续深耕,加强品牌方合作。考虑到自有品牌成长超预期,我们将公司2025-2026 年归母净利润预测由1.4/1.9 亿元上调至1.9/2.8亿元,新增2027 年归母净利润预测4.0 亿元,同比 +80%/+48%/+40%,对应PE 分别为43/29/21X,维持"买入"评级。 风险提示:品牌商解约或产品质量不佳、自有品牌销售不及预期、行业竞争加剧等。 公司披露2024 年年报及2025Q1 业绩:2024 年公司实现营收17.66 亿元(+2 ...
若羽臣(003010):绽家持续绽放 斐萃接力增长
Xin Lang Cai Jing· 2025-04-29 02:48
Core Viewpoint - The company reported its financial results for 2024 and Q1 2025, showing strong growth in revenue and net profit, driven by its proprietary brands and improved cash flow [1][2][3] Financial Performance - For 2024, revenue reached 1.77 billion, a year-on-year increase of 29.3%, with net profit attributable to shareholders at 110 million, up 94.6% [1] - In Q1 2025, revenue was 570 million, reflecting a 54.2% year-on-year growth, and net profit attributable to shareholders was 30 million, increasing by 113.9% [1] - The company proposed a cash dividend of 5 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [1] Profitability and Cost Structure - The gross margin for 2024 was 44.6%, up 4.3 percentage points, while the net profit margin was 6.0%, an increase of 2.0 percentage points [1] - Sales expense ratio rose to 29.8%, up 2.0 percentage points due to increased marketing costs from business growth; management expense ratio decreased to 5.6%, down 1.3 percentage points; R&D expense ratio was 1.5%, down 0.3 percentage points [1] Operational Efficiency - By the end of 2024, accounts receivable stood at 200 million, a 17.6% increase year-on-year; net cash flow from operating activities improved significantly to 330 million, attributed to optimized inventory turnover and reduced stock levels [1] Brand Performance - The proprietary brand "Zhenjia" showed remarkable growth, with revenue of 480 million in 2024, a 90.1% increase, and a gross margin of 66.9% [2] - The brand management segment generated 500 million in revenue, a 212.24% increase, although its gross margin decreased to 30.5% [2] Channel Performance - Online sales reached 1.71 billion, up 26.7%, with a gross margin of 60.5%; offline sales were 50 million, a staggering 295.34% increase, but with a gross margin decline to 43.6% [2] Strategic Developments - The company’s proprietary brands have significantly contributed to performance, with "Zhenjia" and "Ficui" achieving over 100% growth in GMV across multiple channels [3] - The brand management business has attracted notable partners, enhancing GMV growth for brands like Bayer and Aveeno, while also expanding into personal care and health products [3] Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 170 million, 220 million, and 270 million respectively, with corresponding PE ratios of 47, 37, and 30 [3]
若羽臣(003010):绽家持续绽放,斐萃接力增长
上 市 公 司 商贸零售 2025 年 04 月 28 日 若羽臣 (003010) ——绽家持续绽放,斐萃接力增长 报告原因:有业绩公布需要点评 买入(维持) | 市场数据: | 2025 年 04 月 25 日 | | --- | --- | | 收盘价(元) | 49.91 | | 一年内最高/最低(元) | 54.00/10.03 | | 市净率 | 7.7 | | 股息率%(分红/股价) | 0.60 | | 流通 A 股市值(百万元) | 6,035 | | 上证指数/深证成指 | 3,295.06/9,917.06 | | 注:"股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产(元) | 6.49 | | 资产负债率% | 35.75 | | 总股本/流通 A 股(百万) | 164/121 | | 流通 B 股/H 股(百万) | -/- | 一年内股价与大盘对比走势: 04-25 05-25 06-25 07-25 08-25 09-25 10-25 11-25 12-25 01-25 02-25 ...
若羽臣:2024年报及2025年一季报点评:绽家快速放量,保健品斐萃打造第二成长曲线-20250428
Soochow Securities· 2025-04-28 01:55
证券研究报告·公司点评报告·互联网电商 若羽臣(003010) 2024 年报及 2025 年一季报点评:绽家快速放量, 保健品斐萃打造第二成长曲线 2025 年 04 月 27 日 买入(维持) | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 1,366 | 1,766 | 2,685 | 3,634 | 4,762 | | 同比(%) | 12.25 | 29.26 | 52.06 | 35.34 | 31.04 | | 归母净利润(百万元) | 54.29 | 105.64 | 189.82 | 281.49 | 395.46 | | 同比(%) | 60.93 | 94.58 | 79.70 | 48.29 | 40.49 | | EPS-最新摊薄(元/股) | 0.33 | 0.64 | 1.16 | 1.72 | 2.41 | | P/E(现价&最新摊薄) | 150.80 | 77.50 | 43.13 | 29 ...